Skip to main content
Top
Published in: Population Health Metrics 1/2016

Open Access 01-12-2016 | Review

Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions

Authors: Adam D. M. Briggs, Jane Wolstenholme, Tony Blakely, Peter Scarborough

Published in: Population Health Metrics | Issue 1/2016

Login to get access

Abstract

Non-communicable diseases are the leading global causes of mortality and morbidity. Growing pressures on health services and on social care have led to increasing calls for a greater emphasis to be placed on prevention. In order for decisionmakers to make informed judgements about how to best spend finite public health resources, they must be able to quantify the anticipated costs, benefits, and opportunity costs of each prevention option available. This review presents a taxonomy of epidemiological model structures and applies it to the economic evaluation of public health interventions for non-communicable diseases. Through a novel discussion of the pros and cons of model structures and examples of their application to public health interventions, it suggests that individual-level models may be better than population-level models for estimating the effects of population heterogeneity. Furthermore, model structures allowing for interactions between populations, their environment, and time are often better suited to complex multifaceted interventions. Other influences on the choice of model structure include time and available resources, and the availability and relevance of previously developed models. This review will help guide modelers in the emerging field of public health economic modeling of non-communicable diseases.
Literature
1.
go back to reference GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71.CrossRef GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71.CrossRef
2.
go back to reference Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.CrossRefPubMedPubMedCentral Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.CrossRefPubMedPubMedCentral
3.
go back to reference Murray CJL, Richards MA, Newton JN, et al. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet. 2013;381:997–1020.CrossRefPubMed Murray CJL, Richards MA, Newton JN, et al. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet. 2013;381:997–1020.CrossRefPubMed
5.
go back to reference Kelly M, Morgan A, Ellis S, Younger T, Huntley J, Swann C. Evidence based public health: a review of the experience of the National Institute of Health and Clinical Excellence (NICE) of developing public health guidance in England. Soc Sci Med. 2010;71:1056–62.CrossRefPubMed Kelly M, Morgan A, Ellis S, Younger T, Huntley J, Swann C. Evidence based public health: a review of the experience of the National Institute of Health and Clinical Excellence (NICE) of developing public health guidance in England. Soc Sci Med. 2010;71:1056–62.CrossRefPubMed
10.
go back to reference Fischer AJ, Threlfall A, Meah S, Cookson R, Rutter H, Kelly MP. The appraisal of public health interventions: an overview. J Public Health. 2013;35:488–94.CrossRef Fischer AJ, Threlfall A, Meah S, Cookson R, Rutter H, Kelly MP. The appraisal of public health interventions: an overview. J Public Health. 2013;35:488–94.CrossRef
11.
go back to reference Threlfall AG, Meah S, Fischer AJ, Cookson R, Rutter H, Kelly MP. The appraisal of public health interventions: the use of theory. J Public Health. 2015;37:166–71.CrossRef Threlfall AG, Meah S, Fischer AJ, Cookson R, Rutter H, Kelly MP. The appraisal of public health interventions: the use of theory. J Public Health. 2015;37:166–71.CrossRef
12.
go back to reference Marsh K, Phillips CJ, Fordham R, Bertranou E, Hale J. Estimating cost-effectiveness in public health: a summary of modelling and valuation methods. Health Econ Rev. 2012;2. Marsh K, Phillips CJ, Fordham R, Bertranou E, Hale J. Estimating cost-effectiveness in public health: a summary of modelling and valuation methods. Health Econ Rev. 2012;2.
13.
go back to reference Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, Rice N, Sculpher M, Sowden A. Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy. 2009;93:85–92.CrossRefPubMed Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, Rice N, Sculpher M, Sowden A. Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy. 2009;93:85–92.CrossRefPubMed
15.
go back to reference Edwards RT, Charles JM, Lloyd-Williams H. Public health economics: a systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues. BMC Public Health. 2013;13:1001.CrossRefPubMedPubMedCentral Edwards RT, Charles JM, Lloyd-Williams H. Public health economics: a systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues. BMC Public Health. 2013;13:1001.CrossRefPubMedPubMedCentral
16.
go back to reference Payne K, McAllister M, Davies LM. Valuing the economic benefits of complex interventions: when maximising health is not sufficient. Health Econ. 2013;22:258–71.CrossRefPubMed Payne K, McAllister M, Davies LM. Valuing the economic benefits of complex interventions: when maximising health is not sufficient. Health Econ. 2013;22:258–71.CrossRefPubMed
19.
go back to reference Cooper K, Brailsford SC, Davies R. Choice of modelling technique for evaluating health care interventions. J Oper Res Soc. 2007;58:168–76.CrossRef Cooper K, Brailsford SC, Davies R. Choice of modelling technique for evaluating health care interventions. J Oper Res Soc. 2007;58:168–76.CrossRef
20.
go back to reference Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health. 2012;15:796–803.CrossRefPubMed Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health. 2012;15:796–803.CrossRefPubMed
21.
go back to reference Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. Value Health. 2012;15:843–50.CrossRefPubMed Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. Value Health. 2012;15:843–50.CrossRefPubMed
23.
go back to reference Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy. 2004;9:110–8.CrossRefPubMed Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy. 2004;9:110–8.CrossRefPubMed
24.
go back to reference Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15:1295–310.CrossRefPubMed Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15:1295–310.CrossRefPubMed
26.
go back to reference Groot Koerkamp B, Stijnen T, Weinstein MC, Hunink MGM. The combined analysis of uncertainty and patient heterogeneity in medical decision models. Med Decis Making. 2011;31:650–61.CrossRefPubMed Groot Koerkamp B, Stijnen T, Weinstein MC, Hunink MGM. The combined analysis of uncertainty and patient heterogeneity in medical decision models. Med Decis Making. 2011;31:650–61.CrossRefPubMed
27.
go back to reference Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.CrossRefPubMed Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.CrossRefPubMed
29.
go back to reference Trueman P, Anokye NK. Applying economic evaluation to public health interventions: the case of interventions to promote physical activity. J Public Health. 2013;35:32–9.CrossRef Trueman P, Anokye NK. Applying economic evaluation to public health interventions: the case of interventions to promote physical activity. J Public Health. 2013;35:32–9.CrossRef
30.
go back to reference Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370:2044–53.CrossRefPubMed Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370:2044–53.CrossRefPubMed
31.
go back to reference Dallongeville J, Dauchet L, de Mouzon O, Réquillart V, Soler LG. Increasing fruit and vegetable consumption: a cost-effectiveness analysis of public policies. Eur J Public Health. 2011;21:69–73.CrossRefPubMed Dallongeville J, Dauchet L, de Mouzon O, Réquillart V, Soler LG. Increasing fruit and vegetable consumption: a cost-effectiveness analysis of public policies. Eur J Public Health. 2011;21:69–73.CrossRefPubMed
32.
go back to reference Trogdon J, Finkelstein EA, Reyes M, Dietz WH. A return-on-investment simulation model of workplace obesity interventions. J Occup Environ Med. 2009;51:751–8.CrossRefPubMed Trogdon J, Finkelstein EA, Reyes M, Dietz WH. A return-on-investment simulation model of workplace obesity interventions. J Occup Environ Med. 2009;51:751–8.CrossRefPubMed
33.
go back to reference Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26:497–511.CrossRefPubMed Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26:497–511.CrossRefPubMed
34.
go back to reference Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork AC, Aubin HJ. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries. Eur J Public Health. 2009;19:650–4.CrossRefPubMed Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork AC, Aubin HJ. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries. Eur J Public Health. 2009;19:650–4.CrossRefPubMed
35.
go back to reference Hoogendoorn M, Welsing P, Rutten-van Mölken MPMH. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008;24:51–61.CrossRefPubMed Hoogendoorn M, Welsing P, Rutten-van Mölken MPMH. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008;24:51–61.CrossRefPubMed
36.
go back to reference Jacobs-van der Bruggen MAM, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM, Baan CA. Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care. 2007;30:128–34.CrossRefPubMed Jacobs-van der Bruggen MAM, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM, Baan CA. Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care. 2007;30:128–34.CrossRefPubMed
37.
go back to reference Bemelmans W, van Baal P, Wendel-Vos W, Schuit J, Feskens E, Ament A, Hoogenveen R. The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action. Prev Med. 2008;46:127–32.CrossRefPubMed Bemelmans W, van Baal P, Wendel-Vos W, Schuit J, Feskens E, Ament A, Hoogenveen R. The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action. Prev Med. 2008;46:127–32.CrossRefPubMed
38.
go back to reference van Gils PF, Over EAB, Hamberg-van Reenen HH, de Wit GA, van den Berg M, Schuit AJ, Engelfriet PM. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open. 2011;1, e000363.PubMedPubMedCentral van Gils PF, Over EAB, Hamberg-van Reenen HH, de Wit GA, van den Berg M, Schuit AJ, Engelfriet PM. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open. 2011;1, e000363.PubMedPubMedCentral
39.
go back to reference Hoogenveen RT, van Baal PHM, Boshuizen HC. Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions. Math Med Biol. 2010;27:1–19.CrossRefPubMed Hoogenveen RT, van Baal PHM, Boshuizen HC. Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions. Math Med Biol. 2010;27:1–19.CrossRefPubMed
40.
go back to reference Hurley SF, Matthews JP. The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost Eff Resour Alloc. 2007;5:2.CrossRefPubMedPubMedCentral Hurley SF, Matthews JP. The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost Eff Resour Alloc. 2007;5:2.CrossRefPubMedPubMedCentral
41.
go back to reference Hurley SF, Matthews JP. Cost-effectiveness of the Australian National Tobacco Campaign. Tob Control. 2008;17:379–84.CrossRefPubMed Hurley SF, Matthews JP. Cost-effectiveness of the Australian National Tobacco Campaign. Tob Control. 2008;17:379–84.CrossRefPubMed
42.
go back to reference Roux L, Pratt M, Tengs TO, et al. Cost effectiveness of community-based physical activity interventions. Am J Prev Med. 2008;35:578–88.CrossRefPubMed Roux L, Pratt M, Tengs TO, et al. Cost effectiveness of community-based physical activity interventions. Am J Prev Med. 2008;35:578–88.CrossRefPubMed
43.
go back to reference Liew D, Lim SS, Bertram M, McNeil JJ, Vos T. A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease. Eur J Cardiovasc Prev Rehabil. 2006;13:515–22.CrossRefPubMed Liew D, Lim SS, Bertram M, McNeil JJ, Vos T. A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease. Eur J Cardiovasc Prev Rehabil. 2006;13:515–22.CrossRefPubMed
44.
go back to reference Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124:146–53.CrossRefPubMed Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124:146–53.CrossRefPubMed
45.
go back to reference Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150:243–54.CrossRefPubMed Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150:243–54.CrossRefPubMed
46.
go back to reference Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther. 2004;26:304–21.CrossRefPubMed Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther. 2004;26:304–21.CrossRefPubMed
47.
go back to reference Adarkwah CC, Gandjour A, Akkerman M, Evers SM. Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model. PLoS One. 2011;6, e26139.CrossRefPubMedPubMedCentral Adarkwah CC, Gandjour A, Akkerman M, Evers SM. Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model. PLoS One. 2011;6, e26139.CrossRefPubMedPubMedCentral
48.
go back to reference Galani C, Schneider H, Rutten FFH. Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health. 2007;52:372–82.CrossRefPubMed Galani C, Schneider H, Rutten FFH. Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health. 2007;52:372–82.CrossRefPubMed
49.
go back to reference Lindgren P, Lindström J, Tuomilehto J, Uusitupa M, Peltonen M, Jönsson B, de Faire U, Hellénius ML. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care. 2007;23:177–83.CrossRefPubMed Lindgren P, Lindström J, Tuomilehto J, Uusitupa M, Peltonen M, Jönsson B, de Faire U, Hellénius ML. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care. 2007;23:177–83.CrossRefPubMed
50.
go back to reference Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin. 2008;24:1823–32.CrossRefPubMed Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin. 2008;24:1823–32.CrossRefPubMed
51.
go back to reference Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 2012;30:825–40.CrossRefPubMed Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 2012;30:825–40.CrossRefPubMed
52.
go back to reference Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144:326–36.CrossRefPubMed Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144:326–36.CrossRefPubMed
53.
go back to reference Smith KJ, Hsu HE, Roberts MS, Kramer MK, Orchard TJ, Piatt GA, Seidel MC, Zgibor JC, Bryce CL. Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005–2007. Prev Chronic Dis. 2010;7:A109.PubMedPubMedCentral Smith KJ, Hsu HE, Roberts MS, Kramer MK, Orchard TJ, Piatt GA, Seidel MC, Zgibor JC, Bryce CL. Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005–2007. Prev Chronic Dis. 2010;7:A109.PubMedPubMedCentral
54.
go back to reference Gulliford MC, Charlton J, Bhattarai N, Charlton C, Rudisill C. Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care: population-based cohort study and Markov model. Eur J Heal Econ. 2014;15:341–51.CrossRef Gulliford MC, Charlton J, Bhattarai N, Charlton C, Rudisill C. Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care: population-based cohort study and Markov model. Eur J Heal Econ. 2014;15:341–51.CrossRef
55.
go back to reference Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(1–160):iii–iv.PubMed Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(1–160):iii–iv.PubMed
56.
go back to reference Dalziel K, Segal L. Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions. Health Promot Int. 2007;22:271–83.CrossRefPubMed Dalziel K, Segal L. Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions. Health Promot Int. 2007;22:271–83.CrossRefPubMed
57.
go back to reference Palmer AJ, Tucker DMD. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Prim Care Diabetes. 2012;6:109–21.CrossRefPubMed Palmer AJ, Tucker DMD. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Prim Care Diabetes. 2012;6:109–21.CrossRefPubMed
58.
go back to reference The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of Intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542.CrossRef The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of Intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542.CrossRef
59.
go back to reference Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323–32.CrossRefPubMedPubMedCentral Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323–32.CrossRefPubMedPubMedCentral
61.
62.
go back to reference Dangerfield BC. System dynamics applications to European health care issues. J Oper Res Soc. 1999;50:345–53.CrossRef Dangerfield BC. System dynamics applications to European health care issues. J Oper Res Soc. 1999;50:345–53.CrossRef
63.
go back to reference Macmillan A, Connor J, Witten K, Kearns R, Rees D, Woodward A. The societal costs and benefits of commuter bicycling: simulating the effects of specific policies using system dynamics modeling. Environ Health Perspect. 2014;122:335–44.PubMedPubMedCentral Macmillan A, Connor J, Witten K, Kearns R, Rees D, Woodward A. The societal costs and benefits of commuter bicycling: simulating the effects of specific policies using system dynamics modeling. Environ Health Perspect. 2014;122:335–44.PubMedPubMedCentral
64.
go back to reference Hoogenveen RT, van Baal PH, Boshuizen HC, Feenstra TL. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation. Cost Eff Resour Alloc. 2008;6:1.CrossRefPubMedPubMedCentral Hoogenveen RT, van Baal PH, Boshuizen HC, Feenstra TL. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation. Cost Eff Resour Alloc. 2008;6:1.CrossRefPubMedPubMedCentral
65.
go back to reference Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health. 1987;77:1417–26.CrossRefPubMedPubMedCentral Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health. 1987;77:1417–26.CrossRefPubMedPubMedCentral
66.
go back to reference Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Möller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Making. 2012;32:701–11.CrossRefPubMed Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Möller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Making. 2012;32:701–11.CrossRefPubMed
67.
go back to reference Fone D, Hollinghurst S, Temple M, Round A, Lester N, Weightman A, Roberts K, Coyle E, Bevan G, Palmer S. Systematic review of the use and value of computer simulation modelling in population health and health care delivery. J Public Health Med. 2003;25:325–35.CrossRefPubMed Fone D, Hollinghurst S, Temple M, Round A, Lester N, Weightman A, Roberts K, Coyle E, Bevan G, Palmer S. Systematic review of the use and value of computer simulation modelling in population health and health care delivery. J Public Health Med. 2003;25:325–35.CrossRefPubMed
68.
go back to reference Siebers PO, Macal CM, Garnett J, Buxton D, Pidd M. Discrete-event simulation is dead, long live agent-based simulation! J Simul. 2010;4:204–10.CrossRef Siebers PO, Macal CM, Garnett J, Buxton D, Pidd M. Discrete-event simulation is dead, long live agent-based simulation! J Simul. 2010;4:204–10.CrossRef
69.
go back to reference Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems--the mathematical formulation. J Biomed Inform. 2002;35:37–50.CrossRefPubMed Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems--the mathematical formulation. J Biomed Inform. 2002;35:37–50.CrossRefPubMed
70.
go back to reference Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251–64.CrossRefPubMed Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251–64.CrossRefPubMed
71.
go back to reference Haby MM, Vos T, Carter R, Moodie M, Markwick A, Magnus A, Tay-Teo KS, Swinburn B. A new approach to assessing the health benefit from obesity interventions in children and adolescents: the assessing cost-effectiveness in obesity project. Int J Obes (Lond). 2006;30:1463–75.CrossRef Haby MM, Vos T, Carter R, Moodie M, Markwick A, Magnus A, Tay-Teo KS, Swinburn B. A new approach to assessing the health benefit from obesity interventions in children and adolescents: the assessing cost-effectiveness in obesity project. Int J Obes (Lond). 2006;30:1463–75.CrossRef
72.
go back to reference Forster M, Veerman JL, Barendregt JJ, Vos T. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity. Int J Obes (Lond). 2011;35:1071–8.CrossRef Forster M, Veerman JL, Barendregt JJ, Vos T. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity. Int J Obes (Lond). 2011;35:1071–8.CrossRef
74.
75.
go back to reference Cobiac L, Vos T, Veerman L. Cost-effectiveness of weight watchers and the lighten up to a healthy lifestyle program. Aust N Z J Public Health. 2010;34:240–7.CrossRefPubMed Cobiac L, Vos T, Veerman L. Cost-effectiveness of weight watchers and the lighten up to a healthy lifestyle program. Aust N Z J Public Health. 2010;34:240–7.CrossRefPubMed
76.
go back to reference Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of interventions to reduce dietary salt intake. Heart. 2010;96:1920–5.CrossRefPubMed Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of interventions to reduce dietary salt intake. Heart. 2010;96:1920–5.CrossRefPubMed
77.
go back to reference Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, Rodgers A, Lawes CMM, Evans DB. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361:717–25.CrossRefPubMed Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, Rodgers A, Lawes CMM, Evans DB. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361:717–25.CrossRefPubMed
78.
go back to reference Rubinstein A, García Martí S, Souto A, Ferrante D, Augustovski F. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc. 2009;7:10.CrossRefPubMedPubMedCentral Rubinstein A, García Martí S, Souto A, Ferrante D, Augustovski F. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc. 2009;7:10.CrossRefPubMedPubMedCentral
79.
go back to reference Blakely T, Cobiac LJ, Cleghorn CL, Pearson AL, van der Deen FS, Kvizhinadze G, Nghiem N, McLeod M, Wilson N. Health, health inequality, and cost impacts of annual increases in tobacco tax: multistate life table modeling in New Zealand. PLoS Med. 2015;12, e1001856.CrossRefPubMedPubMedCentral Blakely T, Cobiac LJ, Cleghorn CL, Pearson AL, van der Deen FS, Kvizhinadze G, Nghiem N, McLeod M, Wilson N. Health, health inequality, and cost impacts of annual increases in tobacco tax: multistate life table modeling in New Zealand. PLoS Med. 2015;12, e1001856.CrossRefPubMedPubMedCentral
82.
go back to reference Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376:1775–84.CrossRefPubMed Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376:1775–84.CrossRefPubMed
83.
go back to reference Trueman P, Haynes SM, Felicity Lyons G, et al. Long-term cost-effectiveness of weight management in primary care. Int J Clin Pract. 2010;64:775–83.CrossRefPubMed Trueman P, Haynes SM, Felicity Lyons G, et al. Long-term cost-effectiveness of weight management in primary care. Int J Clin Pract. 2010;64:775–83.CrossRefPubMed
84.
go back to reference Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia. 2010;53:875–81.CrossRefPubMed Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia. 2010;53:875–81.CrossRefPubMed
85.
go back to reference Kang HY, Ko SK, Liew D. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. Clin Ther. 2009;31:2919–30.CrossRefPubMed Kang HY, Ko SK, Liew D. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. Clin Ther. 2009;31:2919–30.CrossRefPubMed
86.
go back to reference Johansson P, Ostenson CG, Hilding AM, Andersson C, Rehnberg C, Tillgren P. A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden. Int J Technol Assess Health Care. 2009;25:350–8.CrossRefPubMed Johansson P, Ostenson CG, Hilding AM, Andersson C, Rehnberg C, Tillgren P. A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden. Int J Technol Assess Health Care. 2009;25:350–8.CrossRefPubMed
87.
go back to reference Feldman I, Hellström L, Johansson P. Heterogeneity in cost-effectiveness of lifestyle counseling for metabolic syndrome risk groups -primary care patients in Sweden. Cost Eff Resour Alloc. 2013;11:19.CrossRefPubMedPubMedCentral Feldman I, Hellström L, Johansson P. Heterogeneity in cost-effectiveness of lifestyle counseling for metabolic syndrome risk groups -primary care patients in Sweden. Cost Eff Resour Alloc. 2013;11:19.CrossRefPubMedPubMedCentral
88.
89.
go back to reference Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics. 2000;17:461–77.CrossRefPubMed Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics. 2000;17:461–77.CrossRefPubMed
Metadata
Title
Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions
Authors
Adam D. M. Briggs
Jane Wolstenholme
Tony Blakely
Peter Scarborough
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Population Health Metrics / Issue 1/2016
Electronic ISSN: 1478-7954
DOI
https://doi.org/10.1186/s12963-016-0085-1

Other articles of this Issue 1/2016

Population Health Metrics 1/2016 Go to the issue